알림

Oragenics Inc. (OGEN)

NYSE American: OGEN · 실시간 가격 · USD

0.55

+0.01 (1.85%)

종가 기준: Aug 18, 2026, 3:59 PM

1.85% (1D)

매수호가	n/a
시가총액	2.46M
매출 (ttm)	n/a
순이익 (ttm)	-10.08M
베타	n/a
EPS (ttm)	-1.45
P/E (ttm)	n/a
선행 P/E	-0.05
P/B (ttm)	0.39
P/S (ttm)	n/a
Earnings Date	n/a

매도호가	n/a
거래량	38,993
평균 거래량 (20일)	38,916
시가	0.54
전일 종가	0.54
일중 범위	0.53 - 0.56
52주 범위	0.48 - 1.45
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

OGEN 소개

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene ampli...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Feb 25, 2004

직원 수 3

상장 거래소 NYSE American

티커 OGEN

웹사이트 https://www.oragenics.com

전체 기업 정보

재무 실적

2025년 Oragenics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -9.84M로, -6.86% 감소했습니다.

재무제표

어닝 서프라이즈

Oragenics가 May 12, 2023에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -42.3 예상치 상회 47.71, 및 53.01% 전년 대비 성장.

뉴스

6개월 전 · TipRanks

Oragenics previews targeted milestones for 2026

Oragenics (OGEN) previewed its targeted milestones for 2026. Oragenics is advancing its lead candidate ONP-002, a novel intranasal neurosteroid, through clinical studies as the potential first and onl...

6개월 전 · TipRanks

Oragenics partners with Duck Flats Pharma to support FDA IND trial design

Oragenics (OGEN) announced it has engaged Duck Flats Pharma as its U.S. Investigational New Drug, IND, readiness and regulatory execution partner to support FDA-facing preparation and clinical trial d...

9개월 전 · Associated Press Finance

Oragenics: Q3 Earnings Snapshot

SARASOTA, Fla. AP) — Oragenics Inc. OGEN) on Friday reported a loss of $3.1 million in its third quarter.

10개월 전 · Pharmaceutical Technology

Oragenics partners Receptor.AI for brain health candidate portfolio

The partnership will harness AI modelling techniques to determine the ideal receptor binding profiles for new compounds.

Oragenics Inc. (OGEN)